Table 3.

Interrupted time series analysis parameters of the volume of medicines in group 1 (‘two category’ market)

Active pharmaceutical ingredient	Referent			Bioequivalents
	Estimate	95% CI	P value	Estimate	95% CI	P value
Zidovudine
Level before the intervention (${\beta }_0$)	0.60	0.47 to 0.74	0.00	Too few points before the intervention
Trend before the intervention (${\beta }_1$)	−0.01	−0.02 to 0	0.22
Level change after the intervention (${\beta }_2$)	−0.26	−0.66 to 0.14	0.19
Trend change after the intervention (${\beta }_3$)	Product disappeared from the market after the intervention date
Verapamil
Level before the intervention (${\beta }_0$)	0.66	0.62 to 0.71	0	4.94	4.44 to 5.44	0.00
Trend before the intervention (${\beta }_1$)	−0.01	−0.01 to −0.01	0.00	0.01	−0.03 to 0.05	0.56
Level change after the intervention (${\beta }_2$)	−0.02	−0.08 to 0.03	0.37	0.67	−0.79 to 2.13	0.36
Trend change after the intervention (${\beta }_3$)	0.01	0.01 to 0.01	0.00	0.01	−0.05 to 0.06	0.82
Ciclosporin
Level before the intervention (${\beta }_0$)	4.10	3.78 to 4.43	0.00	0.10	0.06 to 0.14	0.00
Trend before the intervention (${\beta }_1$)	0.00	−0.02 to 0.02	0.92	0.02	0.02 to 0.02	0.00
Level change after the intervention (${\beta }_2$)	−0.29	−0.53 to −0.04	0.02	−0.15	−0.25 to −0.05	0.00
Trend change after the intervention (${\beta }_3$)	−0.01	−0.03 to 0.01	0.45	0.01	0 to 0.01	0.07
Clomipramine
Level before the intervention (${\beta }_0$)	3.47	2.89 to 4.05	0.00	2.84	1.83 to 3.86	0.00
Trend before the intervention (${\beta }_1$)	−0.03	−0.08 to 0.01	0.14	0.06	0.01 to 0.1	0.02
Level change after the intervention (${\beta }_2$)	−0.25	−0.93 to 0.44	0.47	−1.50	−2.62 to −0.38	0.01
Trend change after the intervention (${\beta }_3$)	0.03	−0.04 to 0.11	0.39	−0.08	−0.15 to −0.01	0.03
Tacrolimus
Level before the intervention (${\beta }_0$)	3.43	3.19 to 3.67	0.00	2.63	2.37 to 2.88	0.00
Trend before the intervention (${\beta }_1$)	0.04	0.03 to 0.05	0.00	0.01	0 to 0.02	0.16
Level change after the intervention (${\beta }_2$)	−0.09	−0.4 to 0.23	0.58	0.07	−0.21 to 0.35	0.63
Trend change after the intervention (${\beta }_3$)	−0.02	−0.04 to 0	0.06	0.08	0.05 to 0.1	0.00
Acenocoumarol
Level before the intervention (${\beta }_0$)	109.28	107.3 to 111.25	0.00	30.82	29.99 to 31.66	0.00
Trend before the intervention (${\beta }_1$)	−0.73	−0.86 to −0.61	0.00	0.70	0.63 to 0.78	0.00
Level change after the intervention (${\beta }_2$)	−3.57	−6.08 to −1.07	0.01	−0.62	−2.79 to 1.55	0.57
Trend change after the intervention (${\beta }_3$)	−0.23	−0.37 to −0.09	0.00	−0.16	−0.28 to −0.03	0.01
Mycophenolate mofetil
Level before the intervention (${\beta }_0$)	3.69	3.37 to 4	0.00	3.31	2.88 to 3.73	0.00
Trend before the intervention (${\beta }_1$)	0.04	0.01 to 0.06	0.00	0.15	0.11 to 0.18	0.00
Level change after the intervention (${\beta }_2$)	0.28	−0.19 to 0.75	0.24	0.38	−0.35 to 1.12	0.30
Trend change after the intervention (${\beta }_3$)	−0.02	−0.04 to 0.01	0.20	−0.04	−0.08 to 0	0.05

We are considering a p value less than 0.05 as a statistically significant value. Bold means p value <0.05.

Units used in this analysis are the number of daily defined doses of the active pharmaceutical ingredients included.